Literature DB >> 32301304

[New antibiotics for the clinical setting, an overview].

Sylvain Meylan1, Vera Portillo Tunon2, Benoît Guery1.   

Abstract

Antibiotic resistance has become a major medical problem of our time. In 2015, the World Health Organisation (WHO) endorsed a global action plan in response. One of the main axes of this plan has been the sustained development of new antimicrobials. Despite its challenges, over half a dozen new substances have become clinically available in the last decade. Here, we review a selection of these novel antimicrobial and their applications and discuss their possible use in the clinical setting.

Mesh:

Substances:

Year:  2020        PMID: 32301304

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  1 in total

Review 1.  Development of Anti-Virulence Therapeutics against Mono-ADP-Ribosyltransferase Toxins.

Authors:  Miguel R Lugo; Allan R Merrill
Journal:  Toxins (Basel)       Date:  2020-12-25       Impact factor: 4.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.